Table 55. Patient characteristics–haloperidol versus ziprasidone

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Vieta et al. 2005**32 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Bipolar  ***DSM Classification:*** DSM IV  ***Study period:*** NR  ***Number of centers:*** Multicenter(n = 76)  ***Setting:*** Inpatient  ***Country:*** Spain  ***Financial support:*** Industry (Bristol–Myers Squibb, Otsuka)  ***Washout period performed:*** yes (1–3 days)  ***Run-in phase performed:*** no  ***Followup period:*** 12 wks | ***Main inclusion criteria:*** DSM–IV Dx of bipolar I disorder  ***Main exclusion criteria:*** Presence of rapid–cycling bipolar I disorder; duration of the current manic episode of more than 4 weeks; proven substance misuse; pts considered unresponsive to antipsychotics; recent Tx with a long–acting antipsychotic, lithium or divalproate | ***G1:***  ***Age (mean±SD):*** 41.00 ± 11.80  ***Males (n(%)):*** 57/172 (31.9%)  ***Ethnicity:*** NR  ***BL symptom scores:*** BPRS (mean±SD): 4.90 ± 1.31  YMRS (mean±SD): 31.50 ± 7.87  ***G2:***  ***Age (mean±SD):*** 40.80±10.80  ***Males (n(%)):*** 244/336 (72.6%)  ***Ethnicity:*** NR  ***BL symptom scores:*** BPRS (mean±SD):  5.00 ± 1.32  YMRS (mean±SD): 31.10 ±6.61 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Haloperidol  ***Dosage:*** 10–15mg  ***Intervals:*** NR  ***G2:***  ***Classification:*** SGA  ***Drug:*** Aripiprazole  ***Dosage:*** 15–30mg  ***Intervals:*** NR |

AP = antipsychotic; BID = Twice daily; BL = baseline; BPRS = Brief Psychiatric Rating Scale; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; FGA = first-generation antipsychotic; mg = milligram; n = number; NR = not reported; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; wk = week; YMRS = Young Mania Rating Scale; yr = year